ABX 1431

Drug Profile

ABX 1431

Alternative Names: ABX-1431; ABX-1431 HCl

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abide Therapeutics
  • Developer Abide Therapeutics; University of Oxford
  • Class Analgesics; Anti-inflammatories; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists; Monoacylglycerol lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gilles de la Tourette's syndrome; Neurological disorders; Neuropathic pain; Non-ulcer dyspepsia; Pain

Most Recent Events

  • 31 Mar 2018 Abide Therapeutics and University of Oxford completes the phase I trial in Pain in United Kingdom (PO) (NCT02929264)
  • 28 Mar 2018 Abide Therapeutics regained worldwide rights to ABX 1431 and terminates its licence with Celgene Corporation
  • 28 Nov 2017 Topline efficacy and safety data from phase Ib trial of ABX 1431 in Gilles de la Tourette's syndrome released by Abide Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top